Results 231 to 240 of about 259,945 (244)

Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer. [PDF]

Oncol Res
Liu K, Xue X, Qin H, Zhu J, Jin M, Dai D, Tang Y, Bukhari I, Liu H, Qiu C, Ren F, Zheng P, Mi Y, Chen W.   +13 more
europepmc   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

PD-L1 expression in schistosomal granuloma: an immunohistochemical study in urinary bladder schistosomiasis. [PDF]

J Clin Pathol
Elhalaby RE, Zeina WO, Nessim L, Ahmed ME, Kamel NN, Anis SE, Dong H, Cheville JC, Kwon ED.   +8 more
europepmc   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Erratum: Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation [Corrigendum]. [PDF]

Cancer Manag Res
europepmc   +1 more source

CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosis. [PDF]

Transl Oncol
Witzleben AV, Remark R, Idel C, Ribbat-Idel J, Krupar R, Schröck A, Klümper N, Doescher J, Sikora AG, Kors TA, Vahl JM, Brand M, Sonntag M, Brunner C, Hoffmann TK, Perner S, Gnjatic S, Laban S.   +17 more
europepmc   +1 more source

Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. [PDF]

Cell Death Dis
Liu Y, Wang N, Li Z, Li N, Hui F, Wang X, Tang G, Zhang Q, Yu G, Liu S, Ding Y.   +10 more
europepmc   +1 more source

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy. [PDF]

Antib Ther
Chen D, Wu Z, Zhao X, Bhatt RS, Yang Y, Zhu W, Tang H, Wang K, Guo C, Liu D, Yang C, Guo H, Bai X, Zhang R, Li S, Tian W.   +15 more
europepmc   +1 more source

Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer. [PDF]

Front Immunol
Wu Q, Tissot S, Peddle A, Yin K, Sagaert X, De Hertogh G, Abdelkader B, Pu T, Van Herpe F, D'Hoore A, Rusakiewicz S, Verbandt S, Tejpar S, Rasschaert G.   +13 more
europepmc   +1 more source